Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...

Vertex Pharmaceuticals Incorporated’s VRTX third-quarter 2025 results were strong as it beat estimates for both earnings and ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Key market opportunities for Cas12 proteins include rising government investments in biotech, increased demand for ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

The US FDA is set to introduce a faster approval process for personalized gene editing therapies, aiming to accelerate investment and development of treatments for rare diseases, highlighted by the ...

Nantucket High School and the Egan Maritime Institute will bring island students to the Marine Biological Laboratory in Woods ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...